Clinical Pathology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Haemophilia. 2011 May;17(3):490-3. doi: 10.1111/j.1365-2516.2010.02447.x. Epub 2011 Mar 4.
Persistence of inhibitors against factor VIII (FVIII) may be a risk factor that increases physical disability in haemophilia A (HA) patients. This study aimed to evaluate prevalence of FVIII inhibitors in previously treated children with severe HA and the impact of persistent inhibitors on knee joint status and lumbar bone mineral density (BMD). Fifty children with severe HA, FVIII <1%; aged 5-16 years were enrolled in this study; they received plasma-derived FVIII on-demand treatment for 50-250 exposure days (EDs). Inhibitors were checked at basal visit and were followed up for 1 year, using Bethesda assay. Cross-sectional clinical scoring and radiological evaluation of the knee joint (by Arnold-Hilgartner staging and Pettersson score), along with lumbar BMD by Dual Energy X-ray Absorptiometry (DEXA) were performed. Patients with persistent inhibitors for 1 to 5 years, median 2.5 years, were 10 (20%). Six had high titre and none of them had completely normal knees, seven had advanced knee arthropathy and six had low lumbar BMD in comparison to 2 and 8 of the 40 patients without inhibitors respectively (P < 0.05). Persistence of inhibitors for more than 2 years without immuno-prophylaxis was a risk factor for joint damage. Low lumbar BMD was found in 88.9% of patients with stages four and five knee arthropathy and in 66.7% of patients with positive hepatitis C. Severe HA children in this Egyptian study had a relatively low prevalence of persistent FVIII inhibitors, which, if not treated, may increase the risk of knee arthropathy and lumbar osteopenia.
抑制物对因子 VIII(FVIII)的持续存在可能是增加血友病 A(HA)患者身体残疾的一个风险因素。本研究旨在评估先前接受过治疗的重度 HA 儿童中 FVIII 抑制剂的流行情况,以及持续性抑制剂对膝关节状况和腰椎骨密度(BMD)的影响。本研究纳入了 50 名年龄在 5-16 岁、FVIII<1%的重度 HA 患儿,他们接受了按需给予的血浆源性 FVIII 治疗,暴露时间为 50-250 个治疗日(EDs)。在基线检查时检查抑制剂,并使用 Bethesda 测定法进行为期 1 年的随访。对膝关节进行横断面临床评分和影像学评估(采用 Arnold-Hilgartner 分期和 Pettersson 评分),并通过双能 X 射线吸收法(DEXA)测量腰椎 BMD。10 名(20%)患者存在持续 1-5 年(中位数 2.5 年)的抑制剂。其中 6 名患者的抑制剂滴度较高,且他们均无完全正常的膝关节,7 名患者有进展性膝关节关节炎,6 名患者的腰椎 BMD 较低,与无抑制剂的 40 名患者中的 2 名和 8 名相比,差异均有统计学意义(P<0.05)。未进行免疫预防而持续存在抑制剂超过 2 年是发生关节损伤的一个危险因素。在处于膝关节关节炎 4 期和 5 期的患者中,88.9%存在腰椎 BMD 降低,在丙型肝炎阳性的患者中,66.7%存在腰椎 BMD 降低。埃及这项研究中的重度 HA 儿童的持续性 FVIII 抑制剂的流行率相对较低,如果不进行治疗,可能会增加膝关节关节炎和腰椎骨质疏松的风险。